[Nab-paclitaxel (Abraxane) for the treatment of metastatic pancreatic cancer]
Macchiavello D, Rey-Ares L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A
Record ID 32015000884
Spanish
Authors' recommendations:
Scarce evidence of good methodological quality was found. For the treatment of metastatic pancreatic cancer in patients who can not receive FOLFIRINOX, the use of Nab-Paclitaxel associated with Gemcitabine might improve overall survival in less than three months versus Gemcitabine alone in spite of the higher incidence of its adverse events. No studies comparing FOLFIRINOX with Nab-Paclitaxel associated with Gemcitabine have been found.
There is no consensus on its use in the coverage policies consulted due to its high cost and low clinical benefit.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Adult
- Aged
- Disease-Free Survival
- Drug Administration Schedule
- Female
- International Cooperation
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Prognosis
- Treatment Outcome
- Adenocarcinoma
- Albumins
- Antigens, Tumor-Associated, Carbohydrate
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers, Tumor
- Deoxycytidine
- Liver Neoplasms
- Lymphocytes
- Neutrophils
- Paclitaxel
- Pancreatic Neoplasms
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.